Brokerages Set Organon & Co. (NYSE:OGN) Target Price at $8.38

Shares of Organon & Co. (NYSE:OGN) have been given an average rating of “Reduce” by the seven brokerages that are covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $8.3750.

OGN has been the topic of a number of research analyst reports. Wall Street Zen cut shares of Organon & Co. from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Piper Sandler lowered Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price objective on the stock. in a research note on Monday, October 27th. JPMorgan Chase & Co. cut their price objective on Organon & Co. from $14.00 to $12.00 and set an “underweight” rating for the company in a research report on Tuesday, November 11th. Morgan Stanley reduced their target price on Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 11th. Finally, Barclays initiated coverage on Organon & Co. in a research note on Tuesday, December 9th. They issued an “underweight” rating and a $7.50 price target on the stock.

Organon & Co. Price Performance

NYSE:OGN opened at $8.21 on Thursday. The company has a debt-to-equity ratio of 9.69, a quick ratio of 1.20 and a current ratio of 1.75. The stock’s 50-day simple moving average is $7.86 and its 200 day simple moving average is $8.67. The company has a market cap of $2.13 billion, a P/E ratio of 4.28, a P/E/G ratio of 1.75 and a beta of 0.58. Organon & Co. has a 52-week low of $6.18 and a 52-week high of $17.23.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Monday, November 10th. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.93 by $0.08. The company had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a return on equity of 143.47% and a net margin of 7.95%.During the same quarter in the prior year, the firm posted $1.38 EPS. As a group, sell-side analysts forecast that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 11th. Stockholders of record on Thursday, November 20th were given a $0.02 dividend. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $0.08 annualized dividend and a dividend yield of 1.0%. Organon & Co.’s dividend payout ratio is presently 4.17%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Hantz Financial Services Inc. lifted its position in Organon & Co. by 293.8% during the second quarter. Hantz Financial Services Inc. now owns 2,674 shares of the company’s stock worth $26,000 after acquiring an additional 1,995 shares during the last quarter. Foster Dykema Cabot & Partners LLC bought a new position in shares of Organon & Co. during the third quarter worth approximately $29,000. Farther Finance Advisors LLC lifted its holdings in Organon & Co. by 87.8% during the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock worth $31,000 after purchasing an additional 2,033 shares during the last quarter. SouthState Corp boosted its stake in Organon & Co. by 1,857.0% in the 2nd quarter. SouthState Corp now owns 3,914 shares of the company’s stock valued at $38,000 after purchasing an additional 3,714 shares during the period. Finally, Rothschild Investment LLC boosted its stake in Organon & Co. by 73.1% in the 3rd quarter. Rothschild Investment LLC now owns 3,899 shares of the company’s stock valued at $42,000 after purchasing an additional 1,646 shares during the period. Institutional investors and hedge funds own 77.43% of the company’s stock.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.